Citations

Clear

3942 citation(s) found for "To, Van".

Demographics of first‐time donors returning for donation during the pandemic: COVID‐19 convalescent plasma versus standard blood product donors
Buren, Nancy L. Van , Rajbhandary, Srijana , Reynolds, Vanessa, Gorlin, Jed B. , Stramer, Susan L. , Notari, Edward P. , Conti, Galen , Katz, Louis M. , Stubbs, James R. , Buskirk, Camille M. van , Kuttner, Kip, Smith, Debra L. , Ngamsuntikul, Samantha, Pandey, Suchitra , Ward, Dawn C. , Ziman, Alyssa , Hiskey, Matthew , Townsend, Mary , Sachais, Bruce S. , van Buren, Nancy L , van Buskirk, Camille M, Ziman, Alyssa , Rajbhandary, Srijana , Gorlin, Jed

Mayo Clinic

Transfusion | December 23, 2022 | Volume: 63 | Issue: 3 | Pages: 552-563

10.1111/trf.17229 | PMID 36550639 Get It

AbstractBackgroundPrevious studies have demonstrated low first‐time donor return rates (DRR) following catastrophic events. Little is known, however, about the influence of demographic factors on the DRR of first‐time donors during the COVID‐19 pandemic, including the unique motivation of COVID‐19 convalescent plasma (CCP) donors as compared to non‐CCP donors.Study Design and MethodsThirteen blood collection organizations submitted deidentified data from first‐time CCP and non‐CCP donors returning for regular (non‐CCP) donations during the pandemic. DRR was calculated as frequencies. Demographic factors associated with returning donors: race/ethnicity, gender, and generation (Gen Z: 19–24, Millennial: 25–40, Gen X: 41–56, and Boomer: ≥57 years old), within the CCP and non‐CCP first‐time cohorts were compared using chi‐square test at p < .05 statistical significance.ResultsFrom March 2020 through December 2021, there were a total of 44,274 first‐time CCP and 980,201 first‐time non‐CCP donors. DRR were 14.6% (range 11.9%–43.3%) and 46.6% (range 10.0%–76.9%) for CCP and non‐CCP cohorts, respectively. Age over 40 years (Gen X and Boomers), female gender, and White race were each associated with higher return in both donor cohorts (p < .001). For the non‐CCP return donor cohort, the Millennial and Boomers were comparable.ConclusionThe findings demonstrate differences in returning donor trends between the two donor cohorts. The motivation of a first‐time CCP donor may be different than that of a non‐CCP donor. Further study to improve first‐time donor engagement would be worthwhile to expand the donor base with a focus on blood donor diversity emphasizing engagement of underrepresented minorities and younger donors.
APOE2 Exacerbates TDP‐43 Related Toxicity in the Absence of Alzheimer Pathology
Meneses, Axel , Li, Zonghua , O’Leary, Justin , Li, Fuyao , Nakamura, M. , Kurti, Aishe, Heckman, Michael G. , White, Launia J. , Xie, Manling , Chen, Yixing , Finch, NiCole A., Lim, Melina J., Delenclos, Marion , DeTure, Michael , Martin, Nicholas B. , Ikezu, Tadafumi C. , Blitterswijk, Marka van , Wu, Long‐Jun , McLean, Pamela J. , Rademakers, Rosa , Ross, Owen A. , Bu, Guojun , Zhao, Na , Meneses, Axel D , Li, Zonghua , O'Leary, Justin, Li, Fuyao , Chen, Kai , Murakami, Aya , Qiao, Wenhui , Heckman, Michael G , White, Launia, DeTure, Michael A, Linares, Cynthia , van Blitterswijk, Marka M, Ross, Owen A , Dickson, Dennis W , Zhao, Na , van Blitterswijk, Marka , Wu, Long-Jun , Bu, Guojun , Chen, Yixing , Xie, Manling , McLean, Pamela J , Koga, Shunsuke , Chen, Kai , Dickson, Dennis W.

Mayo Clinic

Annals of Neurology | December 22, 2022 | Volume: 93 | Issue: 4 | Pages: 830-843

10.1002/ana.26580 | PMID 36546684 Get It

ObjectiveRecent evidence supports a link between increased TDP‐43 burden and the presence of an APOE4 gene allele in Alzheimer's disease (AD); however, it is difficult to conclude the direct effect of APOE on TDP‐43 pathology due to the presence of mixed AD pathologies. The goal of this study is to address how APOE isoforms impact TDP‐43 pathology and related neurodegeneration in the absence of typical AD pathologies.MethodsWe overexpressed human TDP‐43 via viral transduction in humanized APOE2, APOE3, APOE4 mice, and murine Apoe‐knockout (Apoe‐KO) mice. Behavior tests were performed across ages. Animals were harvested at 11 months of age and TDP‐43 overexpression‐related neurodegeneration and gliosis were assessed. To further address the human relevance, we analyzed the association of APOE with TDP‐43 pathology in 160 postmortem brains from autopsy‐confirmed amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with motor neuron disease (FTLD‐MND) in the Mayo Clinic Brain Bank.ResultsWe found that TDP‐43 overexpression induced motor function deficits, neuronal loss, and gliosis in the motor cortex, especially in APOE2 mice, with much milder or absent effects in APOE3, APOE4, or Apoe‐KO mice. In the motor cortex of the ALS and FTLD‐MND postmortem human brains, we found that the APOE2 allele was associated with more severe TDP‐43‐positive dystrophic neurites.InterpretationOur data suggest a genotype‐specific effect of APOE on TDP‐43 proteinopathy and neurodegeneration in the absence of AD pathology, with the strongest association seen with APOE2. ANN NEUROL 2023;93:830–843
Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline
Fuleihan, Ghada El‐Hajj , Clines, Gregory A. , Hu, Mimi I. , Marcocci, Claudio , Murad, M. Hassan , Piggott, Thomas , Poznak, Catherine Van , Wu, Joy Y. , Drake, Matthew T. , El-Hajj Fuleihan, Ghada , Van Poznak, Catherine , Murad, M Hassan , Drake, Matthew T , Piggott, Thomas

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 22, 2022 | Volume: 108 | Issue: 3 | Pages: 507-528

10.1210/clinem/dgac621 | PMID 36545746 Get It

Abstract Background Hypercalcemia of malignancy (HCM) is the most common metabolic complication of malignancies, but its incidence may be declining due to potent chemotherapeutic agents. The high mortality associated with HCM has declined markedly due to the introduction of increasingly effective chemotherapeutic drugs. Despite the widespread availability of efficacious medications to treat HCM, evidence-based recommendations to manage this debilitating condition are lacking. Objective To develop guidelines for the treatment of adults with HCM. Methods A multidisciplinary panel of clinical experts, together with experts in systematic literature review, identified and prioritized 8 clinical questions related to the treatment of HCM in adult patients. The systematic reviews (SRs) queried electronic databases for studies relevant to the selected questions. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the certainty of evidence and make recommendations. An independent SR was conducted in parallel to assess patients' and physicians' values and preferences, costs, resources needed, acceptability, feasibility, equity, and other domains relevant to the Evidence-to-Decision framework as well as to enable judgements and recommendations. Results The panel recommends (strong recommendation) in adults with HCM treatment with denosumab (Dmab) or an intravenous (IV) bisphosphonate (BP). The following recommendations were based on low certainty of the evidence. The panel suggests (conditional recommendation) (1) in adults with HCM, the use of Dmab rather than an IV BP; (2) in adults with severe HCM, a combination of calcitonin and an IV BP or Dmab therapy as initial treatment; and (3) in adults with refractory/recurrent HCM despite treatment with BP, the use of Dmab. The panel suggests (conditional recommendation) the addition of an IV BP or Dmab in adult patients with hypercalcemia due to tumors associated with high calcitriol levels who are already receiving glucocorticoid therapy but continue to have severe or symptomatic HCM. The panel suggests (conditional recommendation) in adult patients with hypercalcemia due to parathyroid carcinoma, treatment with either a calcimimetic or an antiresorptive (IV BP or Dmab). The panel judges the treatments as probably accessible and feasible for most recommendations but noted variability in costs, resources required, and their impact on equity. Conclusions The panel's recommendations are based on currently available evidence considering the most important outcomes in HCM to patients and key stakeholders. Treatment of the primary malignancy is instrumental for controlling hypercalcemia and preventing its recurrence. The recommendations provide a framework for the medical management of adults with HCM and incorporate important decisional and contextual factors. The guidelines underscore current knowledge gaps that can be used to establish future research agendas.
Clinical Practice Evolvement for Post-Operative Prostate Cancer Radiotherapy—Part 1: Consistent Organs at Risk Management with Advanced Image Guidance
Laughlin, Brady S. , Lo, Stephanie, Vargas, Carlos , Walt, Charles Van Der , Tinnon, Katie, Beckett, Mason, Hobbis, Dean , Wong, William W. , Keole, Sameer R., Rwigema, Jean‐Claude M. , Yu, Nathan Y. , Clouser, Edward , Van der Walt, Charles, Schild, Steven E. , Clouser, Edward Lee , Laughlin, Brady S , DeWees, T.A. , Rong, Yi

Mayo Clinic

Cancers | December 21, 2022 | Volume: 15 | Issue: 1 | Pages: 16

10.3390/cancers15010016 | PMID 36612013 Get It

Purpose: Post-operative prostate cancer patients are treated with full bladder instruction and the use of an endorectal balloon (ERB). We reassessed the efficacy of this practice based on daily image guidance and dose delivery using high-quality iterative reconstructed cone-beam CT (iCBCT). Methods: Fractional dose delivery was calculated on daily iCBCT for 314 fractions from 14 post-operative prostate patients (8 with and 6 without ERB) treated with volumetric modulated radiotherapy (VMAT). All patients were positioned using novel iCBCT during image guidance. The bladder, rectal wall, femoral heads, and prostate bed clinical tumor volume (CTV) were contoured and verified on daily iCBCT. The dose-volume parameters of the contoured organs at risk (OAR) and CTV coverage were assessed for the clinical impact of daily bladder volume variations and the use of ERB. Minimum bladder volume was studied, and a straightforward bladder instruction was explored for easy clinical adoption. Results: A “minimum bladder” contour, the overlap between the original bladder contour and a 15 mm anterior and superior expansion from prostate bed PTV, was confirmed to be effective in identifying cases that might fail a bladder constraint of V65% <60%. The average difference between the maximum and minimum bladder volumes for each patient was 277.1 mL. The daily bladder volumes varied from 62.4 to 590.7 mL and ranged from 29 to 286% of the corresponding planning bladder volume. The bladder constraint of V65% <60% was met in almost all fractions (98%). CTVs (D90%, D95%, and D98%) remained well-covered regardless of the absolute bladder volume daily variation or the presence of the endorectal balloon. Patients with an endorectal balloon showed smaller variation but a higher average maximum rectal wall dose (D0.03mL: 104.3% of the prescription) compared to patients without (103.3%). Conclusions: A “minimum bladder” contour was determined that can be easily generated and followed to ensure sufficient bladder sparing. Further analysis and validation are needed to confirm the utility of the minimal bladder contour. Accurate dose delivery can be achieved for prostate bed target coverage and OAR sparing with or without the use of ERB.
Zika virus alters osteogenic lineage progression of human mesenchymal stromal cells
Mumtaz, Noreen , Dudakovic, Amel , Nair, Asha, Koedam, Marijke, Leeuwen, Johannes P.T.M. van , Rockx, Barry , Wijnen, André J. van , Eerden, Bram C. J. van der , Rockx, Barry , van der Eerden, Bram C J , van Wijnen, Andre J , Koopmans, Marion

Mayo Clinic

Journal of Cellular Physiology | December 20, 2022 | Volume: 238 | Issue: 2 | Pages: 379-392

10.1002/jcp.30933 | PMID 36538650 Get It

AbstractArboviruses target bone forming osteoblasts and perturb bone remodeling via paracrine factors. We previously reported that Zika virus (ZIKV) infection of early‐stage human mesenchymal stromal cells (MSCs) inhibited the osteogenic lineage commitment of MSCs. To understand the physiological interplay between bone development and ZIKV pathogenesis, we employed a primary in vitro model to examine the biological responses of MSCs to ZIKV infection at different stages of osteogenesis. Precommitted MSCs were infected at the late stage of osteogenic stimulation (Day 7) with ZIKV (multiplicity of infection of 5). We observe that MSCs infected at the late stage of differentiation are highly susceptible to ZIKV infection similar to previous observations with early stage infected MSCs (Day 0). However, in contrast to ZIKV infection at the early stage of differentiation, infection at a later stage significantly elevates the key osteogenic markers and calcium content. Comparative RNA sequencing (RNA‐seq) of early and late stage infected MSCs reveals that ZIKV infection alters the mRNA transcriptome during osteogenic induction of MSCs (1251 genes). ZIKV infection provokes a robust antiviral response at both stages of osteogenic differentiation as reflected by the upregulation of interferon responsive genes (n > 140). ZIKV infection enhances the expression of immune‐related genes in early stage MSCs while increasing cell cycle genes in late stage MSCs. Remarkably, ZIKA infection in early stage MSCs also activates lipid metabolism‐related pathways. In conclusion, ZIKV infection has differentiation stage‐dependent effects on MSCs and this mechanistic understanding may permit the development of new therapeutic or preventative measures for bone‐related effects of ZIKV infection.
Examining the effects of sex and age on tau PET binding in the absence of beta‐amyloid pathology
Dincer, Aylin , Keefe, Sarah , Hornbeck, Russ C. , Franklin, Erin , Xiong, Chengjie , Dyck, Christopher H. van , Klein, Gregory , Pariente, Jérémie , Perrin, Richard J. , Gordon, Brian A. , Flores, Shaney , McKay, Nicole S. , Hobbs, Diana A. , Wisch, Julie K. , Jack, Clifford R. , Koeppe, Robert A. , McDade, Eric , Bateman, Randall J. , Morris, John C. , Ances, Beau M. , Benzinger, Tammie L.S.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S5 | Pages: No page available

10.1002/alz.061090 Get It

AbstractBackgroundTau PET imaging is an established tool for studying Alzheimer Disease but its sensitivity to primary age‐related tauopathy (PART) as well as sex effects in individuals without abnormal levels of amyloid are unknown.MethodsCross‐sectional data were collected from 2014 to 2019 in 144 cognitively normal younger, middle‐aged, and older adults free from amyloid pathology as quantified using PET. Regional values of tau PET binding were measured using flortaucipir. Statistical models examined the main effects of increasing age, sex, race, and sub‐threshold levels of amyloid. Secondary analyses also examined the relationship between tau PET binding and iron as measured using T2* weighted imaging and calcification as measured using CT.ResultsThere were significant positive associations between tau binding and age in 19 regions, with the largest effects seen in the inferior temporal cortex (t=4.59), caudate (t=9.58), and putamen (t=12.57). Iron as measured using T2* imaging mediated only a modest (11.9%) amount of the association between age and tau binding. Elevated tracer uptake in females was present in 23 regions in frontal, lateral parietal, and temporal regions including, most prominently the rostral middle frontal gyrus (t=7.48), superior temporal gyrus (t=5.12) and the inferior temporal gyrus (t=4.22). There were no significant effects of race or sub‐threshold levels of amyloid.ConclusionsTau PET is sensitive to primary effects of age in regions consistent with the neuropathological definition of PART although strong age effects in regions of off‐target binding were also present. There was a robust effect of sex, suggesting prior observations of elevated binding in women is not solely a potentiation of Alzheimer pathology but instead represents an ubiquitous phenomenon. Understand how both sex and age impact tracer binding is critical to understanding the utility of PET tracers as well as interpreting tracer values in the context of disease.
Investigation of differentially expressed proteins through neurofibrillary tangle maturation in Alzheimer’s disease using NanoString’s GeoMx Digital Spatial Profiler
Wickland, Daniel P. , Lesser, Elizabeth R. , Kachergus, Jennifer M., Graff‐Radford, Neill R. , Thompson, E. Aubrey , Moloney, Christina M. , Liu, Chia‐Chen , Blitterswijk, Marka van , Dickson, Dennis W. , Murray, Melissa E.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S3 | Pages: No page available

10.1002/alz.066668 Get It

AbstractBackgroundNeurofibrillary tangles are dynamic entities with a lifespan encompassing three maturity levels: intracellular pretangles, intracellular mature tangles, and extracellular ghost tangles. Proteins are suggested to be differentially expressed throughout the tangle lifespan; however, past studies may be limited by spatial expression or number of proteins investigated. We sought to assess differences in protein expression across the tangle lifespan using GeoMxTM Digital Spatial Profiler (DSP) by NanoString, a new technology allowing for spatially derived multiplex investigation.MethodWe used DSP to measure protein expression in hippocampi from Alzheimer’s disease (n=6) and nondemented controls (n=2) using the “Human Neural Cell Profiling Core” and “Alzheimer’s Pathology” module. Regions of interest (ROIs) were classified by the major tangle maturity level recognized by a primary fluorescent conjugated tau antibody. Protein expression was normalized to the geomean of the three housekeeping genes. The tau‐positive segment was specifically analyzed for comparisons. ANOVA was used for group‐wise comparisons and t‐test using the Benjamini‐Yekutieli adjustment for multiple tests was used for pair‐wise comparisons.ResultAs expected, cytoskeletal (e.g., MAP2, Tau) and neuronal (e.g., NeuN) markers generally decreased through the neurofibrillary tangle lifespan (Figure). Markers profiled as neurodegenerative (e.g., amyloid‐β1‐42, APOE, APP) generally increased through tangle maturity levels, except for TDP‐43 which decreased. Interestingly, there was no significant difference in ubiquitin expression. Astrocytic GFAP and S100B expression was significantly increased through each maturity level. Expression of microglial‐specific markers P2RY12 and TMEM119 was significantly elevated in ghost tangles compared to mature tangles. Additional microglial/macrophage markers including Iba‐1 and CD68 were generally increased as neurofibrillary tangles matured. Interestingly, APOE expression remained low in pretangles and mature tangles before dramatically increasing in ghost tangles (Figure).ConclusionOur findings suggest that proteins are differentially expressed throughout the tangle lifespan and the majority followed a monotonically directed pattern. Non‐monotonically directed protein patterns may reflect the death of the neuron during the ghost tangle maturity level. Future studies will test the hypothesis that the microenvironment of the hippocampus is altered with increasing vulnerability to tangle pathology.
Characterizing Amyloid Responsive Microglia in a Cognitively Resilient Patient with Alzheimer’s Disease Neuropathologic Change: A Case Report
Przybelski, Scott A. , Lesnick, Timothy G. , Petersen, Ronald C. , Graff‐Radford, Jonathan , Lee, Eddie B, Reichard, Ross R., Nguyen, Aivi T. , Ramanan, Vijay K. , Knopman, David S. , Jack, Clifford R. , Dickson, Dennis W. , Deerlin, Vivianna M. Van , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S3 | Pages: No page available

10.1002/alz.066640 Get It

AbstractBackgroundCognitive resilience, the discrepancy observed in individuals with high Alzheimer’s disease (AD) neuropathology and near‐normal cognition, is a growing area of study, wherein multiple factors are responsible. Currently, the role of the microglial activation in cognitive resilience is unknown. Herein described is a case report characterizing the amyloid responsive microglia (ARM) in an 88‐year‐old male decedent homozygous for APOE E4, clinically cognitively intact, and found to have AD neuropathologic change (ADNC) upon autopsy.MethodThe participant was enrolled in the Mayo Clinic Study of Aging (MCSA) and continuously followed for 14 years from 73‐ to 87‐years‐old, wherein serial MRI and clinical assessments were obtained. An autopsy was performed upon death, and routine neuropathologic sections were taken. Formalin‐fixed, paraffin‐embedded sections were stained with H&E, and single immunohistochemistry was performed using antibodies against tau (AT8), beta‐amyloid (6F3D), alpha‐synuclein (LB509), TDP‐43 (pS409/410), and CD163 (10D6). Digital image analysis was performed on dorsolateral prefrontal cortex sections scanned at 40x (Leica GT450). ARM (CD163% area) and beta‐amyloid (% area) measurements were obtained using QuPath threshold classifiers. Descriptive statistics were performed (Graphpad).ResultThe decedent was an 88‐year‐old male, homozygous for APOE E4, with a history of three cardiovascular and metabolic conditions, and lifelong smoking. His MMSE (average 28/30) and global cognition (average ‐0.51) were relatively stable (Figure 1), with no clinical concerns for cognitive impairment. Cortical thickness was normal (temporal meta‐ROI>3 mm) on four serial MRIs. The participant reported high cognitive, physical activities, and education‐occupation scores (upper quartile for the 70+ population). Neuropathologic evaluation was notable for severe cerebral amyloid angiopathy, high ADNC (A3B3C3), and remote microinfarcts. CD163‐positive ARM were observed in the neocortices and perivascular spaces, and the ARM:beta‐amyloid ratio was 0.26 (Figure 1). This ARM:beta‐amyloid ratio trended upwards (>90th percentile) compared to APOE E4/E4‐matched‐ and age‐matched controls provided from the University of Pennsylvania.ConclusionThis case report demonstrates a cognitively resilient individual with an elevated ARM:amyloid ratio. Conversely, lower ARM ratios were observed in a cognitively impaired cohort, raising the possibility ARM may associate with cognition. ARM may represent a protective and phagocytic population, and further studies correlating microglia, cognition, and putative mechanism are required.
Examining the effects of age and sex on tau PET binding in the absence of beta‐amyloid pathology
Gordon, Brian A. , Dincer, Aylin , Keefe, Sarah , Hobbs, Diana A. , Hornbeck, Russ C. , Franklin, Erin , Dyck, Christopher H. van , Klein, Gregory , Pariente, Jérémie , Bateman, Randall J. , Morris, John C. , Perrin, Richard J. , Gordon, Brian A , Bateman, Randall J , Morris, John C , Flores, Shaney , McKay, Nicole S. , Wisch, Julie K. , Jack, Clifford R. , Koeppe, Robert A. , Xiong, Chengjie , McDade, Eric , Benzinger, Tammie L.S.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S1 | Pages: No page available

10.1002/alz.063285 Get It

AbstractBackgroundTau PET imaging is an established tool for studying Alzheimer Disease but its sensitivity to primary age‐related tauopathy (PART) as well as sex effects in individuals without abnormal levels of amyloid are unknown.MethodsCross‐sectional data were collected from 2014 to 2019 in 144 cognitively normal younger, middle‐aged, and older adults free from amyloid pathology as quantified using PET. Regional values of tau PET binding were measured using flortaucipir. Statistical models examined the main effects of increasing age, sex, race, and subthreshold levels of amyloid. Secondary analyses also examined the relationship between tau PET binding and iron as measured using T2* weighted imaging and calcification as measured using CT.ResultsThere were significant positive associations between tau binding and age in 19 regions, with the largest effects seen in the inferior temporal cortex (t=4.59), caudate (t=9.58), and putamen (t=12.57). Iron as measured using T2* imaging mediated only a modest (11.9%) amount of the association between age and tau binding. Elevated tracer uptake in females was present in 23 regions in frontal, lateral parietal, and temporal regions including, most prominently the rostral middle frontal gyrus (t=7.48), superior temporal gyrus (t=5.12) and the inferior temporal gyrus (t=4.22). There were no significant effects of race or subthreshold levels of amyloid.ConclusionsTau PET is sensitive to primary effects of age in regions consistent with the neuropathological definition of PART although strong age effects in regions of off‐target binding were also present. There was a robust effect of sex, suggesting prior observations of elevated binding in women is not solely a potentiation of Alzheimer pathology but instead represents an ubiquitous phenomenon. Understand how both sex and age impact tracer binding is critical to understanding the utility of PET tracers as well as interpreting tracer values in the context of disease.